Here’s the latest high-level update on HPV vaccines.
-
Global guidance on single-dose schedules: The WHO approved a single-dose HPV vaccination option for certain vaccines to simplify delivery and expand coverage, potentially speeding up protection in more settings. This could help reach more girls and reduce cervical cancer risk in low-resource areas.[2]
-
New multi-valent vaccine development: Merck signaled plans to advance a novel multivalent HPV vaccine to broaden protection across additional HPV types, and to study newer dosing regimens for GARDASIL 9, including single-dose regimens in both females and males. These efforts aim to enhance protection and simplify immunization programs.[1]
-
Global vaccination impact: International efforts, including support from Gavi, indicate substantial progress in expanding HPV vaccine coverage to prevent cervical cancer, with tens of millions of girls reached and a projected reduction in cancer deaths as coverage improves. This progress is especially notable in high-burden regions where delivery challenges persist.[3]
-
Therapeutic vaccine research: There is ongoing exploration of therapeutic HPV vaccines that could treat existing HPV infections or precancerous lesions, representing a potential shift from purely preventive vaccines to treatment options in the long term. This research is still under development and not yet part of standard care.[4]
-
Regional rollout and sourcing: Several regions are planning or expanding HPV vaccine programs, including national immunization plans and procurement efforts to secure sufficient doses, with schedules depending on local health authority approvals. Timelines vary by country and program maturity.[6]
-
Notable recent headlines: Coverage gains and milestone announcements from major health organizations and media reflect ongoing momentum in HPV vaccination, including updates on single-dose approval and expanded access initiatives.[1][3]
If you’d like, I can fetch the most current official sources for your area (UK/England) and summarize any local updates, including vaccination schedules, age groups, and any recent changes to the national immunization program. I can also pull a short, cited briefing for quick sharing with colleagues.
Sources
Innovative vaccines are being developed that could potentially treat dangerous human papillomavirus (HPV) infections in adults and therefore reduce risks of cervical cancer, according to a new report released today by the World Health Organization (WHO).
www.who.intCompany reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, the company also plans to conduct clinical trials in both females and males to evaluate the...
www.merck.comWHO announced that a fourth WHO-prequalified human papillomavirus (HPV) vaccine product, Cecolin® ha
www.who.intHigh-risk strains of HPV lead to cervical cancer. Get pap smears HPV test at Brooklyn gynecology. If you're 45 and haven’t gotten HPV vaccine, now its time
www.thewomenschoice.comOne of the big headlines from a major scientific meeting recently: The HPV vaccine not only prevents cervical cancer but reduces the risk of multiple other cancers and even pre-malignant lesions.
www.urmc.rochester.eduhpv vaccine Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. hpv vaccine Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.comA 'concerning' number of students are missing out on the crucial HPV vaccines, says health minister
www.independent.co.ukAnd other health stories from Morning Rounds
www.statnews.com